Baird’s Impax Laboratories, Inc. IPXL Stock Holding History

Baird’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-9,263	Closed	-$278K	–	1216
2014 Q2	$278K	Sell	9,263 -12,005	-56%	-$324K	﹤0.01%	1003
2014 Q1	$562K	Buy	21,268 +525	+3%	+$13.1K	0.01%	818
2013 Q4	$521K	Buy	20,743 +351	+2%	+$7.83K	0.01%	827
2013 Q3	$417K	Sell	20,392 -171	-0.8%	-$3.53K	0.01%	850
2013 Q2	$410K	Buy	+20,563	New	+$365K	0.01%	825

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Baird's IPXL Position: Q3 2014 in Review

Baird sold out of Impax Laboratories, Inc. (IPXL) in Q3 2014, closing a stake of 9,263 shares — an estimated $278K sold.

Baird first reported a position in IPXL in Q2 2013 and held it in 5 quarters. The position peaked at $562K in Q1 2014. 162 funds tracked by Wall St. Rank hold IPXL as of Q3 2014.

Baird reported no remaining Impax Laboratories, Inc. position as of Q3 2014 after selling out during the quarter.
Baird sold 9,263 Impax Laboratories, Inc. shares in Q3 2014, an estimated $278K.
Baird first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 5 quarters.
Baird's Impax Laboratories, Inc. position peaked at $562K in Q1 2014.
162 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2014.

Based on Baird's 13F filing for Q3 2014, filed 12 Nov 2014.